BridgeBio Pharma

Yahoo Finance • 8 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the... Full story

Yahoo Finance • 10 days ago

BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds. Analysts at Piper Sandler have reaffirmed their ‘Overweight’ rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with an unchanged... Full story

Yahoo Finance • 14 days ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reductio... Full story

Yahoo Finance • 17 days ago

Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock?

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story

Yahoo Finance • 20 days ago

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clini... Full story

Yahoo Finance • 27 days ago

How The Parts Add Up: SCHK Headed For $35

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • last month

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therap... Full story

Yahoo Finance • last month

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an inv... Full story

Yahoo Finance • last month

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of... Full story

Yahoo Finance • last month

BridgeBio says new Attruby data adds to benefit in ATTR-CM

[Cardiomyopathy] Hailshadow/iStock via Getty Images * New data from an open-label study of BridgeBio Pharma's (NASDAQ:BBIO [https://seekingalpha.com/symbol/BBIO]) Attruby (acoramidis) showed that the drug led to a significant reduction... Full story

Yahoo Finance • last month

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - Acoramidis also demonstrated a signifi... Full story

Yahoo Finance • 2 months ago

BridgeBio to Participate in September Investor Conferences

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its managemen... Full story

Yahoo Finance • 2 months ago

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral pres... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma (BBIO) president sells shares worth $871k

Thomas Trimarchi, President and CFO of BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold a total of 17,353 shares of common stock on August 18th, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction come... Full story

Yahoo Finance • 2 months ago

Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM market expansion

Alnylam Pharmaceuticals (NASDAQ:ALNY), a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, has been making significant strides in the treatment of rare diseases, particularly transthyretin-mediated am... Full story

Yahoo Finance • 2 months ago

BRIDGEBIO PHARMA INC (NASDAQ:BBIO) Shows Strong Technical Breakout Potential with High Momentum and Consolidation Setup

Technical breakout strategies focus on identifying stocks with solid momentum that are consolidating before their next upward move. The method uses two main metrics: the CHARTMILL TECHNICAL RATING, which measures a stock’s overall trend st... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves premarket: McDonald's, Snap, Super Micro Computer, Walt Disney and more

Check out the companies making headlines in premarket trading. McDonald's — Shares of the fast food giant gained more than 4% after second-quarter results surpassed analyst estimates. McDonald's earned $3.19 per share after adjustments on... Full story

Yahoo Finance • 2 months ago

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate for a biotech de-SPAC transaction since 202... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves after hours: Snap, Rivian, AMD, Super Micro, Arista Networks and more

Check out the companies making headlines in extended trading. Snap — The social media platform plunged 14% after missing revenue expectations for the second quarter. Snap said it recorded $1.34 billion, slightly under the consensus forecas... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma Inc (NASDAQ:BBIO) Shares Drop 11% After Q2 2025 Earnings Miss Despite Revenue Beat

BRIDGEBIO PHARMA INC (NASDAQ:BBIO [https://www.chartmill.com/stock/quote/BBIO]) REPORTS MIXED Q2 2025 RESULTS AS MARKET REACTS NEGATIVELY BridgeBio Pharma Inc released its second-quarter 2025 financial results, delivering a mixed performa... Full story